UCLA CARE Center

Offering state-of-the-art medical care and clinical trials for people living with HIV and AIDS.

About UCLA CARE Center

The UCLA Center for Clinical AIDS Research and Education (CARE) provides state-of-the-art medical care and conducts clinical trials for people living with HIV and AIDS. Our highly trained, nationally recognized physicians are leaders in the field of HIV Medicine, Infectious Diseases, Oncology and other areas relevant to the health of our patients. The CARE Center’s research team is committed to conducting a broad program of ethical and high quality clinical, behavioral and prevention research to promote the health of people living with or at risk for acquiring HIV and other infectious diseases.

Get Involved

To find out more about our CARE Center services, call 310-557-2273.

A flyer for a HIV prevention research study that say, "PrEP against HIV in those unexpected moments."

PrEP Against HIV in Those Unexpected Moments.

Want more on-demand PrEP options?

A5394: A Clinical Trial for People Living with HIV & Chronic Hepatitis B

This trial is for people living with both HIV and chronic hepatitis B, who are taking medicines to control both viruses. The trial is looking at the safety and effectiveness of Selgantolimod, an experimental drug to treat chronic hepatitis B.

A photo a SCRABBLE Board with HIV and HBV spelled out on the side of the board with the caption "Will this study spell IMPROVEMENT for you?" overlayed on top of the Scrabble board.

Latest News

A masthead for a journal article titled, "Impact of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV "

Impact of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV

Host factors associated with the humoral repertoire in the COVID-negative cohort enhance our understanding of these important shifts among PWH.

A masthead for a journal article titled, "Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection "

Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection

Symptom or viral relapse in the absence of antiviral treatment is common, but the combination of symptom and viral rebound is rare.

A masthead for a journal articled titled, "Development and Validation of a Liquid Chromatographic-Tandem Mass Spectrometric Assay for the Quantification of Cabotegravir and Rilpivirine from Dried Blood Spots"

Development and Validation of a Liquid Chromatographic-Tandem Mass Spectrometric Assay for the Quantification of Cabotegravir and Rilpivirine from Dried Blood Spots

The authors developed and validated a novel LC-MS/MS assay for the quantification of CAB and RPV from DBS, and identified conversion factors to estimate plasma concentrations from spotted blood.

In The Know: A Community Webinar Highlighting New Insights in HIV and COVID Research

Program
Click on the presentation title or presenter below to watch that specific presentation.

Get in Touch

To find out more about our CARE Center services, call 310-557-2273.